Uri Weinberg

7.7k total citations
114 papers, 1.8k citations indexed

About

Uri Weinberg is a scholar working on Biomedical Engineering, Genetics and Molecular Biology. According to data from OpenAlex, Uri Weinberg has authored 114 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Biomedical Engineering, 34 papers in Genetics and 26 papers in Molecular Biology. Recurrent topics in Uri Weinberg's work include Glioma Diagnosis and Treatment (34 papers), 3D Printing in Biomedical Research (19 papers) and Nanoplatforms for cancer theranostics (14 papers). Uri Weinberg is often cited by papers focused on Glioma Diagnosis and Treatment (34 papers), 3D Printing in Biomedical Research (19 papers) and Nanoplatforms for cancer theranostics (14 papers). Uri Weinberg collaborates with scholars based in Switzerland, United States and Israel. Uri Weinberg's co-authors include Eilon D. Kirson, Yoram Palti, Moshe Giladi, Rosa S. Schneiderman, Yaara Porat, Tali Voloshin, Mijal Munster, Elijah J. Mun, Daniel D. Von Hoff and Hani M. Babiker and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Uri Weinberg

103 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Uri Weinberg Switzerland 18 724 676 494 337 311 114 1.8k
Moshe Giladi United States 19 662 0.9× 674 1.0× 456 0.9× 295 0.9× 248 0.8× 121 1.6k
Tali Voloshin Israel 19 495 0.7× 441 0.7× 490 1.0× 232 0.7× 404 1.3× 79 1.4k
Yoram Wasserman Israel 9 590 0.8× 693 1.0× 415 0.8× 261 0.8× 159 0.5× 14 1.7k
Mijal Munster United States 12 414 0.6× 338 0.5× 238 0.5× 190 0.6× 158 0.5× 51 878
Maria Vinci Italy 17 377 0.5× 603 0.9× 894 1.8× 192 0.6× 604 1.9× 46 2.1k
Daniel Mordechovich Switzerland 4 406 0.6× 419 0.6× 248 0.5× 174 0.5× 123 0.4× 6 1.0k
Vladimír Dbalý Czechia 7 392 0.5× 348 0.5× 232 0.5× 169 0.5× 148 0.5× 9 1.0k
Jerónimo Blanco Spain 30 436 0.6× 366 0.5× 1.2k 2.5× 134 0.4× 323 1.0× 66 2.1k
Lingna Li United States 27 279 0.4× 566 0.8× 1.5k 3.1× 146 0.4× 482 1.5× 80 3.5k
Anna Shteingauz Israel 13 288 0.4× 261 0.4× 415 0.8× 139 0.4× 147 0.5× 40 969

Countries citing papers authored by Uri Weinberg

Since Specialization
Citations

This map shows the geographic impact of Uri Weinberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uri Weinberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uri Weinberg more than expected).

Fields of papers citing papers by Uri Weinberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Uri Weinberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uri Weinberg. The network helps show where Uri Weinberg may publish in the future.

Co-authorship network of co-authors of Uri Weinberg

This figure shows the co-authorship network connecting the top 25 collaborators of Uri Weinberg. A scholar is included among the top collaborators of Uri Weinberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Uri Weinberg. Uri Weinberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Voloshin, Tali, et al.. (2023). P10.08.B PI3K INHIBITION FOR SENSITIZING CANCER CELLS TO TUMOR TREATING FIELDS (TTFIELDS). Neuro-Oncology. 25(Supplement_2). ii63–ii63.
2.
3.
Blatt, Roni, Mijal Munster, Anna Shteingauz, et al.. (2021). In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso. Frontiers in Oncology. 11. 670809–670809. 20 indexed citations
4.
Voloshin, Tali, Noa Kaynan, Yaara Porat, et al.. (2020). Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunology Immunotherapy. 69(7). 1191–1204. 114 indexed citations
5.
Tempel-Brami, Catherine, Einav Zeevi, Rosa S. Schneiderman, et al.. (2020). P-261 Safety and effectiveness of tumor treating fields combined with sorafenib in preclinical models of hepatocellular carcinoma. Annals of Oncology. 31. S175–S175. 1 indexed citations
6.
Urman, Noa, et al.. (2019). P2.06-21 Efficacy and Safety of Tumor Treating Fields Delivery to the Thorax by Computational Simulations. Journal of Thoracic Oncology. 14(10). S763–S763. 1 indexed citations
7.
Weinberg, Uri, et al.. (2019). Computational simulations to determine the effectiveness and thermal safety of tumor treating fields with delivery to the abdomen. Annals of Oncology. 30. iv70–iv71. 2 indexed citations
8.
9.
Shteingauz, Anna, Yaara Porat, Tali Voloshin, et al.. (2018). AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). Cell Death and Disease. 9(11). 1074–1074. 82 indexed citations
10.
Weinberg, Uri, et al.. (2017). TTFields combined with PD-1 inhibitors or docetaxel for 2nd line treatment of non-small cell lung cancer (NSCLC): Phase 3 LUNAR study. Annals of Oncology. 28. ii51–ii51. 2 indexed citations
11.
Weinberg, Uri, et al.. (2017). P2.06-036 LUNAR - A Phase 3 Trial of TTFields in Combination with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1093–S1094. 1 indexed citations
12.
Porat, Yaara, Moshe Giladi, Rosa S. Schneiderman, et al.. (2017). Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields). Journal of Visualized Experiments. 46 indexed citations
13.
Weinberg, Uri, Tali Voloshin, Noa Kaynan, et al.. (2017). Efficacy of Tumor Treating Fields (TTFields) and anti-PD-1 in non-small cell lung cancer (NSCLC) preclinical models. Annals of Oncology. 28. ii11–ii12. 1 indexed citations
14.
Giladi, Moshe, Mijal Munster, Rosa S. Schneiderman, et al.. (2017). Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiation Oncology. 12(1). 206–206. 118 indexed citations
15.
Weinberg, Uri, et al.. (2016). 194TiP: LUNAR: Phase III study of front-line chemotherapy with TTFields for advanced squamous NSCLC. Journal of Thoracic Oncology. 11(4). S141–S141. 3 indexed citations
16.
Grosso, Federica, et al.. (2016). 215TiP: STELLAR – A phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma. Journal of Thoracic Oncology. 11(4). S150–S150. 3 indexed citations
17.
Chaudhry, Aafia, et al.. (2015). NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study. World Journal of Surgical Oncology. 13(1). 316–316. 51 indexed citations
18.
Giladi, Moshe, Uri Weinberg, Rosa S. Schneiderman, et al.. (2014). Alternating Electric Fields (Tumor-Treating Fields Therapy) Can Improve Chemotherapy Treatment Efficacy in Non-Small Cell Lung Cancer Both In Vitro and In Vivo. Seminars in Oncology. 41. S35–S41. 105 indexed citations
19.
Pless, Miklos & Uri Weinberg. (2011). Tumor treating fields: concept, evidence and future. Expert Opinion on Investigational Drugs. 20(8). 1099–1106. 65 indexed citations
20.
Izhak, Liat, Gizi Wildbaum, Uri Weinberg, et al.. (2009). Predominant Expression of CCL2 at the Tumor Site of Prostate Cancer Patients Directs a Selective Loss of Immunological Tolerance to CCL2 That Could Be Amplified in a Beneficial Manner. The Journal of Immunology. 184(2). 1092–1101. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Moshe Giladi Breakdown of academic impact, for papers by Tali Voloshin Breakdown of academic impact, for papers by Yoram Wasserman Breakdown of academic impact, for papers by Mijal Munster Breakdown of academic impact, for papers by Maria Vinci Breakdown of academic impact, for papers by Daniel Mordechovich Breakdown of academic impact, for papers by Vladimír Dbalý Breakdown of academic impact, for papers by Jerónimo Blanco Breakdown of academic impact, for papers by Lingna Li Breakdown of academic impact, for papers by Anna Shteingauz
Rankless by CCL
2026